Expertise in
10
conditions

Dr. Mark A. Socinski

Oncology
AdventHealth Medical Group Oncology & Hematology At Orlando
2501 N Orange Ave Ste 689, 
Orlando, FL 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Offers Telehealth
Expertise in
10
conditions
AdventHealth Medical Group Oncology & Hematology At Orlando
2501 N Orange Ave Ste 689, 
Orlando, FL 

Overview

Mark Socinski is an Oncologist practicing medicine in Orlando, Florida.

Dr. Socinski is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Lung Adenocarcinoma, EGFR Positive Lung Cancer, and Tissue Biopsy.

He is actively involved in clinical research, co-authoring 175 peer reviewed articles and participating in 16 clinical trials. Dr. Socinski is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in NC

Hospital Affiliations

Adventhealth Orlando

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Florida Blue
  • EPO
  • PPO
Freedom Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Health First
  • HMO
  • POS
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

AdventHealth Medical Group Oncology & Hematology at Orlando
2501 N Orange Ave Ste 689, Orlando, FL 32804

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

Detection of Genetic Markers of Lung Cancer Initiation and Progression
Detection of Genetic Markers of Lung Cancer Initiation and Progression
Enrollment Status: Recruiting
Publish Date: October 24, 2025
Intervention Type: Procedure
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: June 27, 2025
Intervention Type: Drug
Study Drug: APL-101
Study Phase: Phase 2
Randomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib (NSC #736511) as Maintenance Therapy in Non-progressing Patients Following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB / IV Non-small Cell Lung Cancer
Randomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib (NSC #736511) as Maintenance Therapy in Non-progressing Patients Following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB / IV Non-small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: June 23, 2026
Intervention Type: Other, Drug
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab as First Line Therapy for Locally Advanced or Metastatic Non-squamous and Squamous Non-small Cell Lung Cancer Subjects (CANOPY-1)
A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab as First Line Therapy for Locally Advanced or Metastatic Non-squamous and Squamous Non-small Cell Lung Cancer Subjects (CANOPY-1)
Enrollment Status: Terminated
Publish Date: June 17, 2026
Intervention Type: Drug
Study Drugs: Canakinumab, Pembrolizumab, Carboplatin, Cisplatin, Paclitaxel, Nab-paclitaxel, Pemetrexed
Study Phase: Phase 3
A Phase 1/2, Open-Label, Multi-Center Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CLN-081 in Patients With Locally-Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Previously Received Platinum-Based Systemic Chemotherapy
A Phase 1/2, Open-Label, Multi-Center Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CLN-081 in Patients With Locally-Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Previously Received Platinum-Based Systemic Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Drug
Study Drug: CLN-081
Study Phase: Phase 1/Phase 2
Phase I Study of Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC
Phase I Study of Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: May 15, 2026
Intervention Type: Drug
Study Drugs: Ceritinib, Docetaxel
Study Phase: Phase 1
A Phase 3, Randomized, Double-Blind Study of Ociperlimab, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer
A Phase 3, Randomized, Double-Blind Study of Ociperlimab, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: May 12, 2026
Intervention Type: Drug
Study Drugs: Tislelizumab, Ociperlimab, Pembrolizumab
Study Phase: Phase 3
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2025
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
A Phase 2 Study of VLS-101 in Patients With Solid Tumors
A Phase 2 Study of VLS-101 in Patients With Solid Tumors
Enrollment Status: Terminated
Publish Date: November 10, 2025
Intervention Type: Drug
Study Drug: VLS-101
Study Phase: Phase 2
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)
Enrollment Status: Active_not_recruiting
Publish Date: May 23, 2025
Intervention Type: Drug
Study Drugs: ONC-392, Pembrolizumab
Study Phase: Phase 1/Phase 2
View 8 Less Clinical Trials

175 Total Publications

Erratum: Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions.
Erratum: Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 14, 2026
Similar Doctors
Expertise in
20
conditions
Expertise in
20
conditions
Referral may be required

AHMG Oncology And Hematology At Orlando

2501 N Orange Ave Ste 689, 
Orlando, FL 
 (0.1 miles away)
321-732-5395
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Guru Sonpavde is an Oncologist practicing medicine in Orlando, Florida. Dr. Sonpavde is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Urothelial Cancer, Bladder Cancer, Muscle Invasive Bladder Cancer, Orchiectomy, and Nephrectomy. Dr. Sonpavde is currently accepting new patients.

Expertise in
106
conditions
Expertise in
106
conditions
Referral may be required

AdventHealth Medical Group Oncology & Hematology At Orlando

2501 N Orange Ave Ste 689, 
Orlando, FL 
 (0.1 miles away)
754-255-6741
Languages Spoken:
English, Arabic, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Tarek Mekhail is an Oncologist practicing medicine in Orlando, Florida. Dr. Mekhail is highly rated in 106 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, Small Cell Lung Cancer (SCLC), and Tissue Biopsy. Dr. Mekhail is currently accepting new patients.

Expertise in
21
conditions
Expertise in
21
conditions
Referral may be required

AdventHealth Medical Group Neuro Oncology At

2501 N Orange Ave Ste 286, 
Orlando, FL 
 (0.1 miles away)
407-303-2770
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Herbert Newton is an Oncologist practicing medicine in Orlando, Florida. Dr. Newton is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Glioma, Brain Tumor, Astrocytoma, and Glioblastoma. Dr. Newton is currently accepting new patients.

Frequently Asked Questions about Dr. Mark A. Socinski

How do I make an appointment with Dr. Mark A. Socinski?

You can book an appointment with Dr. Mark A. Socinski by calling their office at 386-406-8205. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Mark A. Socinski a top-rated expert for Non-Small Cell Lung Cancer (NSCLC)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mark A. Socinski is classified as an Elite expert for Non-Small Cell Lung Cancer (NSCLC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mark A. Socinski specialize in?

While Dr. Mark A. Socinski is a Oncology, they have specific expertise in Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, and Lung Adenocarcinoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Mark A. Socinski participate in research or clinical trials?

Yes. Dr. Mark A. Socinski has published 175 articles and abstracts on conditions like Non-Small Cell Lung Cancer (NSCLC). You can view a list of Dr. Mark A. Socinski's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Mark A. Socinski accept my insurance?

Dr. Mark A. Socinski accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 386-406-8205 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Socinski's expertise for a condition
ConditionClose
View All 16 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile